Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer

This study aimed to (a) determine if DNA methylation is a mechanism of WWOX (WW domain containing oxidoreductase) and FHIT (fragile histidine triad) inactivation in lung, breast and bladder cancers; (b) examine distinct methylation patterns in neoplastic and adjacent tissues and (c) seek correlation of methylation patterns with disease status. Protein expression was detected by immunohistochemistry, and methylation status by methylation-specific PCR (MSP) and sequencing, in lung squamous cell carcinomas and adjacent tissues, invasive breast carcinomas, adjacent tissues and normal mammary tissues and bladder transitional cell carcinomas. Wwox and Fhit expression was reduced in cancers in association with hypermethylation. Differential patterns of WWOX and FHIT methylation were observed in neoplastic vs adjacent non-neoplastic tissues, suggesting that targeted MSP amplification could be useful in following treatment or prevention protocols. WWOX promoter MSP differentiates DNA of lung cancer from DNA of adjacent lung tissue. WWOX and FHIT promoter methylation is detected in tissue adjacent to breast cancer and WWOX exon 1 MSP distinguishes breast cancer DNA from DNA of adjacent and normal tissue. Differential methylation in cancerous vs adjacent tissues suggests that WWOX and FHIT hypermethylation analyses could enrich a panel of DNA methylation markers.

[1]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[2]  H. Prydz,et al.  Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors , 2002, Oncogene.

[3]  D. Iliopoulos,et al.  The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma , 2004, Cancer.

[4]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[5]  L. D. Barnes,et al.  The role of the FHIT/FRA3B locus in cancer. , 1998, Annual review of genetics.

[6]  C. Croce,et al.  Cancer and the FRA3B/FHIT fragile locus: it's a HIT , 2003, British Journal of Cancer.

[7]  H. Kantarjian,et al.  DNA methylation in haematological malignancies: the role of decitabine , 2003, Expert opinion on investigational drugs.

[8]  Y. Shim,et al.  Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Khuri,et al.  Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[10]  B. Rampy,et al.  The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma , 2000, Cancer.

[11]  D J Porteous,et al.  WWOX: A candidate tumor suppressor gene involved in multiple tumor types , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[13]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.